These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 21225912)

  • 21. Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.
    Jain S; Kapoor G
    Pediatr Blood Cancer; 2010 May; 54(5):783. PubMed ID: 20205256
    [No Abstract]   [Full Text] [Related]  

  • 22. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
    Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
    JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes.
    Dennison JB; Mohutsky MA; Barbuch RJ; Wrighton SA; Hall SD
    J Pharmacol Exp Ther; 2008 Oct; 327(1):248-57. PubMed ID: 18650247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
    Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
    Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
    Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
    Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy.
    Pasternak AL; Marcath LA; Li Y; Nguyen V; Gersch CL; Rae JM; Frame D; Scappaticci G; Kidwell KM; Hertz DL
    Transplant Cell Ther; 2022 Jan; 28(1):19.e1-19.e7. PubMed ID: 34583027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population.
    Ganesapandian M; Ramasamy K; Adithan S; Narayan SK
    Indian J Pharmacol; 2019; 51(6):384-388. PubMed ID: 32029960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia.
    Hartman A; van Schaik RH; van der Heiden IP; Broekhuis MJ; Meier M; den Boer ML; Pieters R
    Leuk Res; 2010 Feb; 34(2):154-9. PubMed ID: 19467705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia.
    Karol SE; Sun Y; Tang L; Pui CH; Ferrolino J; Allison KJ; Cross SJ; Evans WE; Crews KR; Jeha S; Wolf J
    Cancer Med; 2020 Sep; 9(18):6550-6555. PubMed ID: 32710497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
    Ceppi F; Langlois-Pelletier C; Gagné V; Rousseau J; Ciolino C; De Lorenzo S; Kevin KM; Cijov D; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
    Pharmacogenomics; 2014 Jun; 15(8):1105-16. PubMed ID: 25084203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe Vincristine-related Neurotoxicity in 5 Patients With Pediatric Acute Lymphoblastic Leukemia Requiring Discontinuation of Vincristine: A Description of Long-term Outcome.
    Egan-Sherry D; Bhuta R; Cole PD; Gennarini LM; Kahn JM; Sulis ML; DeNardo BD; Welch JJG
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e997-e999. PubMed ID: 34001785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic factors influencing the development of vincristine-induced neurotoxicity.
    Pozzi E; Fumagalli G; Chiorazzi A; Canta A; Cavaletti G
    Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):215-226. PubMed ID: 33283553
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of pyridoxine plus pyridostigmine treatment on vincristine-induced peripheral neuropathy in pediatric patients with acute lymphoblastic leukemia: a single-center experience.
    Aydin Köker S; Gözmen S; Demirağ B; Ünalp A; Karapinar TH; Oymak Y; Gürbüz G; Öner Eİ; Vergin RC
    Neurol Sci; 2021 Sep; 42(9):3681-3686. PubMed ID: 33439396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.
    Zgheib NK; Ghanem KM; Tamim H; Aridi C; Shahine R; Tarek N; Saab R; Abboud MR; El-Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2018 Aug; 28(8):189-195. PubMed ID: 30119132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
    Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
    Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
    McClain CA; Bernhardt MB; Berger A; Bernini JC; Marquez-Do D; Winslow R; Scheurer ME; Schafer ES
    Br J Haematol; 2018 Jun; 181(5):684-687. PubMed ID: 28419449
    [No Abstract]   [Full Text] [Related]  

  • 38. Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.
    Sawaki A; Miyazaki K; Yamaguchi M; Takeuchi T; Kobayashi K; Imai H; Tawara I; Ono R; Nosaka T; Katayama N
    Int J Hematol; 2020 May; 111(5):686-691. PubMed ID: 31993939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
    Saba N; Seal A
    J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective assessment of vincristine-induced peripheral neuropathy in paediatric acute lymphoblastic leukemia.
    Li T; Kandula T; Cohn RJ; Kiernan MC; Park SB; Farrar MA
    Clin Neurophysiol; 2023 Oct; 154():157-168. PubMed ID: 37633123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.